The metabolic hallmark of this glioma subtype is the high level of the oncometabolite 2-hydroxyglutarate (2-HG) by the mutant IDH1 enzyme via the NADPH-dependent reduction of α-ketoglutarate. The gene discussed is IDH1; the disease is glioma.